North America Osteoporosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies) and Forecast, 2020-2027

Table of Content:

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
4. Key Insights
   1. Prevalence of Osteoporosis, Key Countries, 2019
   2. Technology Advances, Osteoporosis Market
   3. New Product Launches, Key Players
   4. Key Developments, Mergers, Acquisitions, etc.
   5. Impact of Covid-19 on the Market
5. North America Osteoporosis Market Analysis, Insights and Forecast, 2016-2027
   1. Key Findings / Summary
   2. Market Analysis, Insights and Forecast – By Drug Class
      1. Bisphosphonate
      2. Hormone Replacement Therapy
      3. Selective Estrogen Receptor Modulator (SERMs)
      4. RANK ligand (RANKL) Inhibitor
      5. Others
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Cardiovascular
   4. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospitals Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
   5. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada
6. Competitive Analysis
   1. Key Industry Developments
   2. Global Market Share Analysis (2019)
   3. Company Profiles (Overview, Products, SWOT, Recent Developments, Strategies, Financials (based on availability))
      1. AbbVie Inc.
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      2. Eli Lilly and Company
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      3. Amgen Inc.
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      4. F. Hoffmann-La Roche Ltd
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      5. Novartis AG
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      6. Sanofi
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      7. Pfizer Inc.
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      8. Merck & Co., Inc.
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      9. GlaxoSmithKline plc
         1. Overview,
         2. Products,
         3. SWOT,
         4. Recent Developments,
         5. Strategies,
         6. Financials (based on availability)
      10. Alcon
          1. Overview,
          2. Products,
          3. SWOT,
          4. Recent Developments,
          5. Strategies,
          6. Financials (based on availability)
      11. Other Prominent Player
          1. Overview,
          2. Products,
          3. SWOT,
          4. Recent Developments,
          5. Strategies,
          6. Financials (based on availability)
7. Strategic Recommendations

List of Figures

Figure 01: North America Osteoporosis Treatment Market Revenue Breakdown (USD billion, %) by Region, 2019 & 2027

Figure 02: North America Osteoporosis Treatment Market Value Share (%), by Technology, 2019 & 2027

Figure 03: North America Osteoporosis Treatment Market Forecast (USD billion), By Bisphosphonate, 2016-2027

Figure 04: North America Osteoporosis Treatment Market Forecast (USD billion), By Hormone Replacement Therapy, 2016-2027

Figure 05: North America Osteoporosis Treatment Market Forecast (USD billion), By Selective Estrogen Receptor Modulator (SERMs), 2016-2027

Figure 06: North America Osteoporosis Treatment Market Forecast (USD billion), By RANK ligand (RANKL) Inhibitor, 2016-2027

Figure 07: North America Osteoporosis Treatment Market Forecast (USD billion), By Others, 2016-2027

Figure 08: North America Osteoporosis Treatment Market Value Share (%), by Route of Administration, 2019 & 2027

Figure 09: North America Osteoporosis Treatment Market Forecast (USD billion), By Oral, 2016-2027

Figure 10: North America Osteoporosis Treatment Market Forecast (USD billion), By Parenteral, 2016-2027

Figure 11: North America Osteoporosis Treatment Market Value Share (%), by Distribution Channel, 2019 & 2027

Figure 12: North America Osteoporosis Treatment Market Forecast (USD billion), By Hospitals Pharmacies, 2016-2027

Figure 13: North America Osteoporosis Treatment Market Forecast (USD billion), By Retail Pharmacies & Stores, 2016-2027

Figure 14: North America Osteoporosis Treatment Market Forecast (USD billion), By Online Pharmacies, 2016-2027

Figure 15: North America Osteoporosis Treatment Market Value (USD billion), by Country, 2019 & 2027

List of Tables

Table 01: North America Osteoporosis Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2016-2027

Table 02: North America Osteoporosis Treatment Market Revenue (USD billion) Forecast, By Route of Administration, 2016-2027

Table 03: North America Osteoporosis Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2016-2027

Table 04: North America Osteoporosis Treatment Market Revenue (USD billion) Forecast, by Country, 2016-2027